Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $215 to $295.
June 27, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $215 to $295.
The raised price target from $215 to $295 by a reputable analyst at Stifel is a strong positive signal for investors. This suggests confidence in the company's future performance and could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100